tsc-101
·Code: TSC-101
tsc-101: sourced relationships with 1 company · 1 clinical trial tracked.
tsc-101 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect tsc-101 to TCRX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could tsc-101 → TCRX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
AML
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| TScan Therapeutics, Inc. (TCRX) AML | Phase 3 |
Clinical Trial Registry Records (1)
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Primary endpoint: Relapse-free survival (RFS)
Interventionalopen310 targetStarted 2026-06Completion 2029-0626 sites · United StatesTScan Therapeutics, Inc.
Frequently asked questions
Which companies have sourced relationships with tsc-101?
tsc-101 has dated SEC/FDA relationship records for TScan Therapeutics, Inc..
How many clinical trials involve tsc-101?
BioSniper tracks 1 clinical trial involving tsc-101.